Salt la conţinut

Oncologie

Managementul anemiei

Agenți de stimulare a eritropoiezei

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (se deschide o fereastră nouă)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Sursă‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Index‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (se deschide o fereastră nouă)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (se deschide o fereastră nouă)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Sursă‎: Acta Haematol 2007;117(3):162-7.

Index‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (se deschide o fereastră nouă)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (se deschide o fereastră nouă)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Sursă‎: Am J Hematol 2013;88(12):990-6.

Index‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (se deschide o fereastră nouă)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (se deschide o fereastră nouă)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Sursă‎: J Clin Oncol 2011;29(28):3791-7.

Index‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (se deschide o fereastră nouă)

Management of anemia in cancer patients. (se deschide o fereastră nouă)

Calabrich A, Katz A.

Sursă‎: Future Oncol 2011;7(4):507-17.

Index‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (se deschide o fereastră nouă)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (se deschide o fereastră nouă)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Sursă‎: BJU Int 2011;108(10):1582-7.

Index‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (se deschide o fereastră nouă)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (se deschide o fereastră nouă)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Sursă‎: J Clin Oncol 2010;28(13):2239-45.

Index‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (se deschide o fereastră nouă)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (se deschide o fereastră nouă)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Sursă‎: Br J Cancer 2011;105(9):1267-72.

Index‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (se deschide o fereastră nouă)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (se deschide o fereastră nouă)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Sursă‎: J Intern Med 2017;281(3):284-99.

Index‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (se deschide o fereastră nouă)

How I treat cancer-associated anemia. (se deschide o fereastră nouă)

Gilreath JA, Rodgers GM

Sursă‎: Blood 2020;136(7):801-13.

Index‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (se deschide o fereastră nouă)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (se deschide o fereastră nouă)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Sursă‎: Eur J Haematol. 2023 110(4):354-61.

Index‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (se deschide o fereastră nouă)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (se deschide o fereastră nouă)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Sursă‎: Cancer 2013;119(1):107-14.

Index‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (se deschide o fereastră nouă)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (se deschide o fereastră nouă)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Sursă‎: J Natl Cancer Inst 2013;105(14):1018-26.

Index‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (se deschide o fereastră nouă)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (se deschide o fereastră nouă)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Sursă‎: Support Care Cancer 2012;20(1):159-65.

Index‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (se deschide o fereastră nouă)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (se deschide o fereastră nouă)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Sursă‎: Leuk Lymphoma. 2019;60(9):2324-7.

Index‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (se deschide o fereastră nouă)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (se deschide o fereastră nouă)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Sursă‎: Oncologist 2010;15(9):935-43.

Index‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (se deschide o fereastră nouă)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (se deschide o fereastră nouă)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Sursă‎: Lung Cancer 2012;76(3):478-85.

Index‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (se deschide o fereastră nouă)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (se deschide o fereastră nouă)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Sursă‎: Eur J Haematol 2016;97(1):33-8.

Index‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (se deschide o fereastră nouă)

Fier intravenos

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (se deschide o fereastră nouă)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Sursă‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Index‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (se deschide o fereastră nouă)

Intravenous iron in oncology. (se deschide o fereastră nouă)

Auerbach M, Ballard H.

Sursă‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Index‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (se deschide o fereastră nouă)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (se deschide o fereastră nouă)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Sursă‎: Int J Colorectal Dis 2016;31(3):543-51.

Index‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (se deschide o fereastră nouă)

How I treat cancer-associated anemia. (se deschide o fereastră nouă)

Gilreath JA, Rodgers GM

Sursă‎: Blood 2020;136(7):801-13.

Index‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (se deschide o fereastră nouă)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (se deschide o fereastră nouă)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Sursă‎: Eur J Haematol. 2023 110(4):354-61.

Index‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (se deschide o fereastră nouă)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (se deschide o fereastră nouă)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Sursă‎: Curr Oncol. 2023 24;30(9):7836-51.

Index‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (se deschide o fereastră nouă)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (se deschide o fereastră nouă)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Sursă‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Index‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (se deschide o fereastră nouă)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (se deschide o fereastră nouă)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Sursă‎: World J Gastroenterol 2014;20(8):1972-85.

Index‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (se deschide o fereastră nouă)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (se deschide o fereastră nouă)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Sursă‎: South Asian J Cancer. 2023 15;12(2):93-9.

Index‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (se deschide o fereastră nouă)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (se deschide o fereastră nouă)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Sursă‎: J Clin Oncol 2008;26(10):1619-25.

Index‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (se deschide o fereastră nouă)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (se deschide o fereastră nouă)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Sursă‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Index‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (se deschide o fereastră nouă)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (se deschide o fereastră nouă)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Sursă‎: Ann Oncol 2013;24(2):475-82.

Index‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (se deschide o fereastră nouă)

ONCOLOGIE
Managementul anemiei
Română
Managementul anemiei
https://assetsnffrgf-a.akamaihd.net/assets/ct/e781f8601f/images/syn_placeholder_sqr.png

Contactați un reprezentant local al Comitetului de legătură cu spitalele

Un serviciu gratuit disponibil la nivel mondial, 24 de ore din 24, pentru medicii care tratează Martori ai lui Iehova.

Contactează-ne

Materiale medicale informative

Subiecte: strategii clinice privind managementul hemoragiei și al anemiei fără transfuzie de sânge; poziția etică și religioasă a Martorilor lui Iehova față de tratamentele medicale; servicii oferite de Martori comunității medicale prin intermediul comitetelor lor de legătură cu spitalele din întreaga lume.

Vizualizează materialele

Materiale video

Opțiuni de tratament și considerente de natură medicală și etică pentru medicii care îi tratează pe Martorii lui Iehova.

Vizualizează materiale video